Product Description
Mechanisms of Action: Lanosterol Synthase Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: SATO Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Tinea
Phase 2: Mycetoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DNDi-FOSR-04-MYC | P2 |
Completed |
Mycetoma |
2021-06-10 |
|
| JapicCTI-152779 | P3 |
Completed |
Tinea |
None |